In the final blog in this series, I want to touch on the evolution of using electronic clinical data in HEDIS measures. Data collection is one of the biggest challenges health plans face in preparation for HEDIS measures. The Electronic Clinical Data Systems (ECDS) framework was designed to increase the efficiency of quality reporting while also providing an incentive to connect to primary clinical information systems. Organizations that successfully report ECDS measures demonstrate interoperability of health data systems in the provision of high-quality care. NCQA’s commitment to the ECDS architecture was bolstered by the standards for interoperability finalized earlier this year.
|
Chronic Obstructive Pulmonary Disease (COPD) is a serious disease that places a heavy burden on affected patients and the healthcare system. Consequently, there are two Pharmacotherapy management measures related to COPD exacerbation for HEDIS Measurement Year 2020 (MY 2020).1 COPD is a group of lung conditions that include emphysema, chronic bronchitis and sometimes asthma. Symptoms of COPD include shortness of breath, cough and sputum production. Exposure to tobacco smoke or air pollutants usually damages the lungs and leads to COPD. Often, COPD patients develop breathing difficulties that become severely worse, known as exacerbations. Serious exacerbations can lead to hospitalization, decreased lung function and possibly death.
|
As discussed in our previous blog, the National Committee for Quality Assurance (NCQA) evaluates and adjusts quality measures each year as they continue development of a core set of meaningful measures for harmonization of performance measurement across the healthcare industry. However, this is the first time the organization has considered changing the timing for these measure deadlines.
|
The National Committee for Quality Assurance (NCQA) HEDIS® set of quality measures is considered by many to be the gold standard when it comes to quality measurement. NCQA continues to pursue a strategy to find a core set of meaningful measures that will allow for the harmonization of performance measurement across the healthcare industry. As such, NCQA will retire a number of measures, streamline and modify existing measures, and add a small number of meaningful measures for HEDIS Measurement Year 2020 (HEDIS MY 2020). This is the first in a four-part blog series in which we’ll be discussing these changes and sharing tips on understanding and incorporating them into your HEDIS strategy.
|
As we wrap up 2019, we invite you to join us in looking back at our most-read blog posts from this past year. In chronological order, here’s the list for 2019. We look forward to sharing more content and more conversations in 2020. Happy New Year!
|
In my final blog in this HEDIS series, I want to touch on the many facets of collecting and using data. Data collection is one of the biggest challenges health plans face in preparation for HEDIS measures.
|
|
|
The current HEDIS Use of Opioids at High Dosage (HDO) measure assesses the percentage of members 18 years of age and older who receive opioid prescriptions at a high dosage.
|